Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient

被引：9

作者：

Trimarchi, Hernan

Lombi, Fernando

Forrester, Mariano

Elizondo, Cristina

Sawinski, Deirdre

Pereyra, Horacio

Freixas, Emilio

机构：

[1] Hosp Britan Buenos Aires, Dept Med, Renal Sect, RA-1280 Buenos Aires, DF, Argentina

[2] Hosp Britan Buenos Aires, Dept Med, Renal Transplant Unit, RA-1280 Buenos Aires, DF, Argentina

[3] Hosp Britan Buenos Aires, Dept Med, Renal Pancreas Transplant Unit, RA-1280 Buenos Aires, DF, Argentina

[4] Hosp Britan Buenos Aires, Div Nephrol, Buenos Aires, DF, Argentina

[5] Hosp Britan Buenos Aires, Internal Med Serv, Buenos Aires, DF, Argentina

[6] Columbia Univ, Med Ctr, New York, NY USA

来源：

NATURE CLINICAL PRACTICE NEPHROLOGY | 2006年 / 2卷 / 08期

关键词：

bisphosphonates; hemodialysis; hypercalcemia; multiple myeloma; pamidronate;

D O I：

10.1038/ncpneph0248

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background A 48-year-old man with a recent diagnosis of multiple myeloma and rapidly progressive oliguric end-stage renal disease requiring hemodialysis, presented with a serum calcium concentration of 3.4 mmol/l (13.6 mg/dl). Investigations Serum laboratory analysis, electroencephalogram, MRI of the brain and bone marrow, and kidney biopsies. Diagnosis Hypercalcemia secondary to multiple myeloma. Management Short-term intravenous disodium pamidronate therapy (30 mg daily) and daily monitoring of serum calcium concentration.

引用

页码：459 / 463

页数：5

共 15 条

[11] ROLE OF ASSAYS FOR PARATHYROID-HORMONE-RELATED PROTEIN IN INVESTIGATION OF HYPERCALCEMIA [J].